Business Context and Reporting Period
Molecular Partners AG, a clinical-stage biopharmaceutical company focused on designed ankyrin repeat proteins (DARPin) for oncology and virology, filed Form 6-K on October 30, 2025. The filing includes unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2025.
Key Financial Metrics
| Metric (CHF thousands) | 9 Months Ended Sep 30, 2025 | 9 Months Ended Sep 30, 2024 | 3 Months Ended Sep 30, 2025 | 3 Months Ended Sep 30, 2024 |
|---|---|---|---|---|
| Revenues | 0 | 4,970 | 0 | 681 |
| Operating Expenses | (45,502) | (51,393) | (12,045) | (15,270) |
| Net Loss | (49,002) | (42,811) | (11,836) | (16,404) |
| Net Loss Per Share (CHF) | (1.32) | (1.29) | (0.33) | (0.49) |
| Cash and Cash Equivalents | 82,359 | 65,752 | 82,359 | 65,752 |
| Short-term Time Deposits | 22,162 | 85,565 | 22,162 | 85,565 |
| Total Shareholders' Equity | 95,529 | 141,636 | 95,529 | 141,636 |
| Net Cash Used in Operating Activities | (40,106) | (46,053) | N/A | N/A |
Note: All figures are in thousands of Swiss Francs (CHF) unless otherwise noted.
Material Changes vs. Prior Period
- Revenue Decline: The company recorded zero revenue for the nine months ended September 30, 2025, compared to CHF 4.97 million in the same period in 2024. This is primarily due to the conclusion of collaboration activities with Novartis in the third quarter of 2024.
- Expense Reduction: Total operating expenses decreased by approximately 11.5% year-over-year (from CHF 51.4 million to CHF 45.5 million), driven by lower R&D and SG&A costs.
- Restructuring Costs: The company incurred CHF 2.73 million in restructuring expenses in the current period, compared to none in the prior year. This relates to a headcount reduction announced in June 2025.
- Financial Results: Net finance results shifted from a gain of CHF 3.6 million in 2024 to a loss of CHF 3.5 million in 2025, largely due to a net foreign exchange loss of CHF 4.77 million on USD-denominated cash balances.
- Liquidity Position: While cash and cash equivalents increased to CHF 82.4 million, short-term time deposits decreased significantly from CHF 85.6 million to CHF 22.2 million, reflecting a net decrease in total liquid assets.
Outlook, Risks, and Management Commentary
- Restructuring Initiative: In June 2025, the company initiated an operational efficiency program impacting 34 positions, primarily in R&D. The majority of the associated cash outflows are expected in the second half of 2025.
- Collaboration Status: The Novartis collaboration has ended. A co-development agreement with Orano Med regarding 212Pb-based Radio Darpin Therapies remains active, with cost-sharing reimbursements recorded as R&D expense adjustments rather than revenue.
- Dividends: The company has not paid dividends since inception and does not anticipate paying them in the foreseeable future.
- Tax Position: The company holds significant tax loss carry-forwards (CHF 195.1 million as of Dec 31, 2024) but has not recognized deferred tax assets due to uncertainty regarding future utilization.
- Share-Based Compensation: Costs increased to CHF 3.45 million for the nine-month period, reflecting ongoing long-term incentive plans (PSUs and RSUs).
Investor Verification Checklist
- Revenue Run Rate: Verify the timeline for potential new revenue-generating collaborations given the cessation of the Novartis agreement.
- Cash Burn Rate: Assess the sustainability of the current cash position (CHF 82.4 million) against the operating cash burn of approximately CHF 40 million for nine months.
- Restructuring Impact: Confirm the actual cash outflow timing for the CHF 2.73 million restructuring charge and the resulting impact on future operating expenses.
- Foreign Exchange Exposure: Review the company's hedging strategy regarding USD-denominated assets, which contributed significantly to the financial loss in the current period.
- Orano Med Collaboration: Evaluate the progress and financial terms of the ongoing partnership with Orano Med as a potential future revenue source.